DDInter776 DDInter927
Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Formoterol {u} (Compound) resembles {v} (Compound) Fenoterol
Formoterol {u} may lead to a major life threatening interaction when taken with {v} Labetalol
Formoterol {u} (Compound) resembles {v} (Compound) Arbutamine
Formoterol {u} (Compound) treats {v} (Disease) chronic obstructive pulmonary disease
Formoterol {u} (Compound) binds {v} (Gene) ADRB1
Formoterol {u} (Compound) upregulates {v} (Gene) HMOX1
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Formoterol {u} (Compound) downregulates {v} (Gene) RPS4Y1
Formoterol {u} (Compound) causes {v} (Side Effect) Anxiety
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Formoterol (Compound) resembles Fenoterol (Compound)
Formoterol may lead to a major life threatening interaction when taken with Labetalol
Formoterol (Compound) resembles Arbutamine (Compound)
Formoterol (Compound) treats chronic obstructive pulmonary disease (Disease)
Formoterol (Compound) binds ADRB1 (Gene)
Formoterol (Compound) upregulates HMOX1 (Gene)
Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Formoterol (Compound) downregulates RPS4Y1 (Gene)
Formoterol (Compound) causes Anxiety (Side Effect)